IMUX Latest Press Releases

-- April 9, 2026 --

Immunic to Participate in Scientific and Medical Conferences in April PRNewswire 6:30 AM

-- April 1, 2026 --

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement PRNewswire 6:30 AM

-- March 31, 2026 --

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton PRNewswire 6:30 AM

-- March 10, 2026 --

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium PRNewswire 6:30 AM

-- March 3, 2026 --

Immunic to Participate in Investor Conferences in March PRNewswire 6:30 AM

-- February 26, 2026 --

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update PRNewswire 6:30 AM

-- February 17, 2026 --

Immunic Announces Closing of Oversubscribed Private Placement Financing PRNewswire 4:05 PM

-- February 13, 2026 --

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company PRNewswire 6:30 AM

-- February 4, 2026 --

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis PRNewswire 6:30 AM

-- January 7, 2026 --

Immunic Highlights 2025 Accomplishments and Upcoming Milestones PRNewswire 6:30 AM

-- November 26, 2025 --

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December PRNewswire 6:30 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software